<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Justice</journal-id><journal-id journal-id-type="iso-abbrev">Health Justice</journal-id><journal-id journal-id-type="pmc-domain-id">3088</journal-id><journal-id journal-id-type="pmc-domain">healthjust</journal-id><journal-title-group><journal-title>Health &amp; Justice</journal-title></journal-title-group><issn pub-type="epub">2194-7899</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12042357</article-id><article-id pub-id-type="pmcid-ver">PMC12042357.1</article-id><article-id pub-id-type="pmcaid">12042357</article-id><article-id pub-id-type="pmcaiid">12042357</article-id><article-id pub-id-type="pmid">40299223</article-id><article-id pub-id-type="doi">10.1186/s40352-025-00336-6</article-id><article-id pub-id-type="publisher-id">336</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Receipt of medications for opioid use disorders among veterans by race/ethnicity and legal involvement: an observational study of electronic health records</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Finlay</surname><given-names initials="AK">Andrea K.</given-names></name><address><email>Andrea.Finlay@va.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pivovarova</surname><given-names initials="E">Ekaterina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="M">Mengfei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Timko</surname><given-names initials="C">Christine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Binswanger</surname><given-names initials="IA">Ingrid A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smelson</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="E">Emmeline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harris</surname><given-names initials="AHS">Alex H. S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00nr17z89</institution-id><institution-id institution-id-type="GRID">grid.280747.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0419 2556</institution-id><institution>VA Palo Alto Health Care System, </institution></institution-wrap>Menlo Park, USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0464eyp60</institution-id><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0742 0364</institution-id><institution>UMass Chan Medical School, </institution></institution-wrap>Worcester, USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t60zh31</institution-id><institution-id institution-id-type="GRID">grid.280062.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9957 7758</institution-id><institution>Kaiser Permanente Colorado, </institution></institution-wrap>Aurora, USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cqn7d42</institution-id><institution-id institution-id-type="GRID">grid.499234.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0433 9255</institution-id><institution>University of Colorado School of Medicine, </institution></institution-wrap>Aurora, USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03fakbf87</institution-id><institution-id institution-id-type="GRID">grid.414593.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 7591 0674</institution-id><institution>Colorado Permanente Medical Group, </institution></institution-wrap>Denver, USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Stanford University School of Medicine, </institution></institution-wrap>Stanford, USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/015nymp25</institution-id><institution-id institution-id-type="GRID">grid.414326.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0626 1381</institution-id><institution>Edith Nourse Rogers Memorial Veterans Hospital, </institution></institution-wrap>Bedford, USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/054spjc55</institution-id><institution-id institution-id-type="GRID">grid.266186.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0684 1394</institution-id><institution>University of Colorado Colorado Springs, </institution></institution-wrap>Colorado Springs, USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046rm7j60</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Kaiser Permanente Bernard J. Tyson School of Medicine, </institution></institution-wrap>Pasadena, USA </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">479093</issue-id><elocation-id>28</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>30</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-01 10:25:47.260"><day>01</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40352_2025_Article_336.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The Veterans Health Administration has made strides to improve access to medications for opioid use disorder overall. However, quality improvement methods to assess treatment gaps may not sufficiently detect differences in medication access by intersecting patient factors, which may have multiplicative rather than additive effects. This study aimed to determine whether race/ethnicity and legal involvement interact in receipt of medications for opioid use disorder among Veterans Health Administration patients.</p></sec><sec><title>Methods</title><p id="Par2">Using national electronic health record data from Fiscal Years 2021&#8211;2022, we examined the receipt of medications for opioid use disorder among veterans diagnosed with opioid use disorder who received healthcare at Veterans Health Administration facilities (<italic toggle="yes">n</italic>&#8201;=&#8201;65,883). We conducted a mixed effects multivariable logistic regression model to examine an interaction effect of race/ethnicity and legal involvement with receipt of any medications for opioid use disorder, both unadjusted and adjusted for patient and facility characteristics.</p></sec><sec><title>Results</title><p id="Par3">In an adjusted logistic regression model, the interaction effect indicated that non-Hispanic Black veterans with legal involvement had the lowest odds of medications for opioid use disorder receipt compared to non-Hispanic White veterans without legal involvement (adjusted odds ratio&#8201;=&#8201;0.67, 95% confidence interval&#8201;=&#8201;0.59&#8211;0.77, <italic toggle="yes">p</italic>&#8201;&lt;.0001). Non-Hispanic American Indian/Alaska Native patients without legal involvement (adjusted odds ratio&#8201;=&#8201;0.85, 95% confidence interval&#8201;=&#8201;0.73&#8211;0.99, <italic toggle="yes">p</italic>&#8201;=.04) also had lower odds of receipt of medications for opioid use disorder compared to non-Hispanic White patients without legal involvement. Non-Hispanic White veterans with legal involvement (adjusted odds ratio&#8201;=&#8201;1.07, 95% confidence interval&#8201;=&#8201;1.01&#8211;1.14, <italic toggle="yes">p</italic>&#8201;=.03) had higher odds of receipt of medications for opioid use disorder compared to non-Hispanic White patients without legal involvement.</p></sec><sec><title>Conclusions</title><p id="Par4">Veterans Health Administration quality improvement efforts should monitor interacting racial and legal status factors and understand and address patient, clinical, and regulatory barriers to medications for opioid use disorder among Black veterans with legal involvement.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Opioid-related disorders</kwd><kwd>Methadone</kwd><kwd>Buprenorphine</kwd><kwd>Naltrexone</kwd><kwd>United States Department of Veterans Affairs</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000738</institution-id><institution>U.S. Department of Veterans Affairs</institution></institution-wrap></funding-source><award-id>IIR 16-239</award-id><award-id>RCS 00-001</award-id><award-id>RCS 14-232</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>K23 DA049953</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">The United States (US) opioid epidemic remains a national public health crisis and veterans have been particularly affected with opioid overdose rates that steadily rose from 2010 to 2016 (Lin et al., <xref ref-type="bibr" rid="CR28">2019</xref>). Among US Veterans Health Administration (VHA) patients, those with a legal history, defined as contact with the Veterans Justice Programs that provide outreach to veterans in court, jail, and prison settings, had 38% higher odds of opioid overdose over a four-year period compared to patients without a legal history (Finlay et al., <xref ref-type="bibr" rid="CR14">2022</xref>). US veterans and non-veterans from racial/ethnic minority backgrounds, such as Black and Hispanic, have been over-represented in the criminal legal system (Pettit &amp; Gutierrez, <xref ref-type="bibr" rid="CR32">2018</xref>; Tsai et al., <xref ref-type="bibr" rid="CR42">2013</xref>). Overdose deaths involving any drug and fentanyl increased among most racial and ethnic groups from 2018 to 2021 (Han et al., <xref ref-type="bibr" rid="CR18">2022</xref>). Among people ages 35 to 64, non-Hispanic Black men and American Indian or Alaskan Native men had the highest overall drug overdose rates and Black men had the highest fentanyl-involved overdose death rates.</p><p id="Par6">Medications for opioid use disorder (MOUD; i.e., methadone, buprenorphine, and extended-release naltrexone) are evidence-based treatments for opioid use disorder and methadone and buprenorphine reduce opioid-related deaths (Department of Veterans Affairs &amp; Department of Defense, <xref ref-type="bibr" rid="CR9">2021</xref>; Volkow et al., <xref ref-type="bibr" rid="CR43">2019</xref>). Within the VHA, it has been a high priority to improve use of MOUD and there have been ongoing efforts to increase prescribing of MOUD since 2006 (Wyse et al., <xref ref-type="bibr" rid="CR45">2018</xref>). Overall, 41% of VHA patients diagnosed with opioid use disorder received one or more types of MOUD in Fiscal Year 2017 (Finlay et al., <xref ref-type="bibr" rid="CR13">2021</xref>). However, there was tremendous variation across the VHA system by location and patient population. Non-Hispanic Black patients, compared to White patients, and patients with legal involvement, compared to patients with no legal involvement, at the VHA, had 0.89 and 0.80 lower odds of receiving MOUD, respectively (Finlay et al., <xref ref-type="bibr" rid="CR13">2021</xref>). However, research examining the interaction between race and legal involvement is needed to ensure that health differences are considered in access to and engagement in treatment programs (Mark et al., <xref ref-type="bibr" rid="CR29">2023</xref>).</p><p id="Par7">Studying the interaction of race and legal status among veterans is important because of known variation by age, race/ethnicity, and sex in drug overdose deaths and lack of information on why these differences exist. Variation in access to MOUD for by racial/ethnic group or legal status may suggest an interaction effect. For example, Black veterans are disproportionately incarcerated compared to White veterans (Tsai et al., <xref ref-type="bibr" rid="CR42">2013</xref>) and MOUD availability is limited in prisons and jails (Scott et al., <xref ref-type="bibr" rid="CR39">2021</xref>; Sufrin et al., <xref ref-type="bibr" rid="CR40">2023</xref>). Black veterans with legal involvement may have fewer opportunities to learn about or initiate MOUD treatment than White veterans. Similarly, Black people arrested on drug charges had fewer opportunities to connect with drug diversion treatment than White people (Nicosia et al., <xref ref-type="bibr" rid="CR31">2013</xref>). When given a choice of medications while incarcerated Black patients were more likely to choose buprenorphine than White patients (Berk et al., <xref ref-type="bibr" rid="CR3">2025</xref>), but in the community buprenorphine is less often prescribed to Black patients compared to White patients (Lagisetty et al., <xref ref-type="bibr" rid="CR27">2019</xref>), suggesting that care may be disrupted for Black patients with legal involvement once they return to their communities. Black patients are also likely to receive lower dosages of methadone and buprenorphine as compared to non-Hispanic White patients in the community, suggesting that even when in agonist treatment, Black patients may be undertreated (Ross et al., <xref ref-type="bibr" rid="CR35">2024</xref>). Black patients also have more distrust of MOUD and the healthcare system than White patients and more often experience criminalization of opioid use (Cuevas et al., <xref ref-type="bibr" rid="CR8">2016</xref>; Husain et al., <xref ref-type="bibr" rid="CR22">2023</xref>; James &amp; Jordan, <xref ref-type="bibr" rid="CR24">2018</xref>; Saha et al., <xref ref-type="bibr" rid="CR36">2008</xref>), which may further deter them from initiating these medications if they fear becoming re-involved in the legal system.</p><p id="Par8">Although the VHA has made strides to improve access to MOUD overall (Wyse et al., <xref ref-type="bibr" rid="CR45">2018</xref>), quality improvement methods to assess gaps in treatment access may not sufficiently detect differences in medication access by interacting patient factors, which may have multiplicative rather than additive effects. The goal of this study was to examine the interaction of race/ethnicity and legal involvement in receipt of MOUD among VHA patients. We hypothesized that patients who were both from racial/ethnic minority groups, such as Black or Hispanic, and legal involved (race * legal involvement) would have lower receipt of MOUD than patients who are non-Hispanic White with no legal involvement.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source and participants</title><p id="Par9">Data were from the VHA Corporate Data Warehouse, which includes all records of veteran patients enrolled in the VHA. Participants included veteran patients who received an opioid use disorder diagnosis during an outpatient or inpatient visit in Fiscal Years 2021 through 2022 (October 1, 2020 through September 30, 2022). The earliest diagnosis record during the observation period was used. This study was approved by the Stanford University Institutional Review Board (#44494) and the VA Palo Alto Research &amp; Development Committee in accordance with the Declaration of Helsinki. All data reported in this manuscript were approved under a waiver of consent.</p></sec><sec id="Sec4"><title>Measures</title><sec id="Sec400"><title>Receipt of any medications for opioid use disorder</title><p id="Par10">The primary outcome measured was receipt of any MOUD, defined following the Version 2 American Society for Addiction Medicine&#8217;s (ASAM) specifications (Harris et al., <xref ref-type="bibr" rid="CR20">2016</xref>). Patients who attended at least one methadone outpatient clinic with a concurrent opioid use disorder diagnosis and/or filled at least one prescription for buprenorphine (oral or injectable) or buprenorphine/naloxone (sublingual) or naltrexone (oral or injectable) during the same Fiscal Year (2021 or 2022) as their opioid use disorder diagnosis were coded as having received MOUD. Veterans with a VA or VA-contracted methadone clinic visit and concurrent opioid use disorder diagnosis were assumed to have received methadone or buprenorphine at the visit. Veterans with a methadone clinic visit and concurrent cancer diagnosis were excluded to ensure methadone receipt was not for pain management. Buprenorphine or naltrexone prescription fills were identified from VA pharmacy records. All facilities had a record of a buprenorphine and all but one facility had a record of a naltrexone prescription fill indicating that these medications were offered at almost all facilities. The ASAM specifications for MOUD (Harris et al., <xref ref-type="bibr" rid="CR20">2016</xref>) were used in this study because these standard specifications were defined and developed using VHA data sources. ASAM specifications are conceptually similar to the US Centers for Medicare &amp; Medicaid Services Use of Pharmacotherapy for Opioid Use Disorder quality measure (Center for Medicaid and CHIP Services, Centers for Medicare &amp; Medicaid Services, <xref ref-type="bibr" rid="CR7">2022</xref>).</p></sec></sec><sec id="Sec401"><title>Race/ethnicity and legal involvement</title><p id="Par11">The primary independent variables were race/ethnicity and legal involvement. Race and ethnicity were drawn from the patient record and coded as Hispanic, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian (including Native Hawaiian/Pacific Islander), non-Hispanic Black, or non-Hispanic White. We examined the distribution of racial groups within the Hispanic category, but because of small sample sizes were unable to analyze them separately.</p><p id="Par12">Patients were coded as with legal involvement if they had an encounter with the VA Veterans Justice Programs as indicated by an outpatient clinic code or Homeless Operations Management and Evaluation System record (Blue-Howells et al., <xref ref-type="bibr" rid="CR4">2013</xref>). Outreach is largely focused on veterans with active or recent criminal legal involvement; therefore, we identified veterans with legal involvement if their encounter with the Veterans Justice Programs occurred within the current or prior Fiscal Year.</p><p id="Par13">The mission of the Veterans Justice Programs is to provide outreach to veterans in criminal legal settings, including courts, jails, and prisons and link them to indicated healthcare, housing and other services (Blue-Howells et al., <xref ref-type="bibr" rid="CR4">2013</xref>). Veterans who had an encounter with Veterans Justice Programs received outreach from VHA staff while involved with the criminal legal system, including while incarcerated in prison or jail, involved in court proceedings, or during or after arrest. We were not able to identify veterans who were involved in the legal system but did not have contact with Veterans Justice Programs. Although VHA staff cannot provide treatment while veterans are incarcerated, outreach specialists meet with veterans in prison or jail, assess their treatment needs including for opioid use disorder, and link veterans after release to VHA and community substance use disorder treatment clinics and other clinics where they can initiation MOUD, if indicated and desired. Veterans with opioid use may be connected to overdose education resources as well.</p></sec><sec id="Sec402"><title>Patient and facility characteristics</title><p id="Par14">We included patient and facility characteristics that were associated with receipt of MOUD in prior studies or were clinically relevant (Finlay et al., <xref ref-type="bibr" rid="CR12">2016a</xref>, <xref ref-type="bibr" rid="CR13">2021</xref>; Knudsen &amp; Roman, <xref ref-type="bibr" rid="CR26">2009</xref>). Patient socio-demographic characteristics included sex (female, male; from the electronic health record), age, marital status, rural or urban residence (defined by the U.S. Census Bureau) (Ratcliffe et al., <xref ref-type="bibr" rid="CR34">2016</xref>), and housing status (defined by International Classification of Diseases-10 codes for homelessness, utilization of VHA homeless services [clinic and bed section codes], and a homeless indicator variable [from a health factors list]) (Finlay et al., <xref ref-type="bibr" rid="CR15">2016</xref>). Patient health characteristics included co-occurring mental health diagnoses, co-occurring substance use disorder diagnoses, the Deyo comorbidity index coded as any versus no comorbidities (Deyo et al., <xref ref-type="bibr" rid="CR11">1992</xref>), and service-connected disability rating, which is based on conditions caused or exacerbated by military service.</p><p id="Par15">Facility characteristics included total number of patients at that facility, the proportion of patients with an opioid use disorder diagnosis at that facility (the number of patients with an opioid use disorder diagnosis divided by the total number of patients), the proportion of women patients at that facility (the number of women patients divided by the total number of patients), and proportion of racial/ethnic minority patients at that facility (the number of Hispanic, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian, and non-Hispanic Black patients divided by the total number of patients). Each facility location was coded as rural or urban and coded by geographic region (i.e., Northeast, South, Midwest, West). Substance use disorder treatment services available at the facility included inpatient withdrawal management, substance use disorder residential treatment, methadone clinic, and percentage of patients who received medications for alcohol use disorder. The focus of this study is on race/ethnicity and legal involvement; therefore, all other patient and facility characteristics were included as controls in the statistical models.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par16">Patients who were diagnosed with opioid use disorder, but who were missing data (<italic toggle="yes">n</italic>&#8201;=&#8201;1350; 2%) were excluded. Descriptive statistics were reported for the total sample and stratified by legal involvement. Differences by legal status were tested using chi-square or t-tests. To examine the association of race/ethnicity and legal involvement with receipt of any MOUD, we conducted a mixed effects multivariable logistic regression model, both unadjusted and adjusted for patient and facility characteristics. To account for clustering, the regression model included a random effect for the facility (<italic toggle="yes">n</italic>&#8201;=&#8201;129) where a veteran received their opioid use disorder diagnosis. We then used the model to produce the predicted population margin of MOUD receipt and 95% confidence intervals among patients in each race/ethnicity by legal involvement group. All analyses were conducted using SAS software version 9.04 (SAS Institute Inc., <xref ref-type="bibr" rid="CR38">2013</xref>). We considered a 2-sided <italic toggle="yes">p</italic>&#8201;&lt;.05 to be statistically significant.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Sample characteristics</title><p id="Par17">A total of <italic toggle="yes">N</italic>&#8201;=&#8201;65,883 patients at 129 VHA facilities in Fiscal Years 2021&#8211;2022 were diagnosed with opioid use disorder (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The sample was 72.5% non-Hispanic White (<italic toggle="yes">n</italic>&#8201;=&#8201;47,748), 10.5% with legal involvement (<italic toggle="yes">n</italic>&#8201;=&#8201;6,908), 8.0% women (<italic toggle="yes">n</italic>&#8201;=&#8201;5,298), with a mean age of 54.9 (standard deviation [SD]&#8201;=&#8201;14.6) years. Co-occurring mental health disorders (patients with legal involvement: 6,039/6,908 [87.4%] and without legal involvement 42,680/58,975 [72.4%]), co-occurring substance use disorders (5,579/6,908 [80.8%] and 27,474/58,975 [46.6%], respectively), and homelessness or participation in a VHA homeless program during the observation period (4,959/6,908 [71.8%] and 24,695/58,975 [41.9%], respectively) were common among both patients groups, but significantly more common among veterans with legal involvement (<italic toggle="yes">p</italic>&#8201;&lt;.001). Sample characteristics are reported overall and by legal status in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par18">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Veterans with opioid use disorders in fiscal years 2021&#8211;2022, overall and stratified by legal involvement</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Overall Sample</th><th align="left" colspan="1" rowspan="1">Veterans With<break/>Legal involvement</th><th align="left" colspan="1" rowspan="1">Veterans Without Legal Involvement</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">N (%)</th><th align="left" colspan="1" rowspan="1">N (%)</th><th align="left" colspan="1" rowspan="1">N (%)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sample size</td><td align="left" colspan="1" rowspan="1">65,883 (100)</td><td align="left" colspan="1" rowspan="1">6,908 (10.5)</td><td align="left" colspan="1" rowspan="1">58,975 (89.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race/Ethnicity</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic American Indian/ Alaskan Native</td><td align="left" colspan="1" rowspan="1">867 (1.3)</td><td align="left" colspan="1" rowspan="1">108 (1.6)</td><td align="left" colspan="1" rowspan="1">759 (1.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Asian</td><td align="left" colspan="1" rowspan="1">775 (1.2)</td><td align="left" colspan="1" rowspan="1">88 (1.3)</td><td align="left" colspan="1" rowspan="1">687 (1.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">12,606 (19.1)</td><td align="left" colspan="1" rowspan="1">1,156 (16.7)</td><td align="left" colspan="1" rowspan="1">11,450 (19.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="left" colspan="1" rowspan="1">3,887 (5.9)</td><td align="left" colspan="1" rowspan="1">403 (5.8)</td><td align="left" colspan="1" rowspan="1">3,484 (5.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">47,748 (72.5)</td><td align="left" colspan="1" rowspan="1">5,153 (74.6)</td><td align="left" colspan="1" rowspan="1">42,595 (72.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.088</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">5,298 (8.0)</td><td align="left" colspan="1" rowspan="1">519 (7.5)</td><td align="left" colspan="1" rowspan="1">4,779 (8.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">60,585 (92.0)</td><td align="left" colspan="1" rowspan="1">6,389 (92.5)</td><td align="left" colspan="1" rowspan="1">54,196 (91.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age &#8211; mean (SD)</td><td align="left" colspan="1" rowspan="1">54.9 (14.6)</td><td align="left" colspan="1" rowspan="1">45.3 (12.6)</td><td align="left" colspan="1" rowspan="1">56.0 (14.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Marital status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Married</td><td align="left" colspan="1" rowspan="1">22,356 (33.9)</td><td align="left" colspan="1" rowspan="1">1,488 (21.5)</td><td align="left" colspan="1" rowspan="1">20,868 (35.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Not married</td><td align="left" colspan="1" rowspan="1">43,527 (66.1)</td><td align="left" colspan="1" rowspan="1">5,420 (78.5)</td><td align="left" colspan="1" rowspan="1">38,107 (64.6)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Residence</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Rural</td><td align="left" colspan="1" rowspan="1">17,070 (25.9)</td><td align="left" colspan="1" rowspan="1">1,579 (22.9)</td><td align="left" colspan="1" rowspan="1">15,491 (26.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urban</td><td align="left" colspan="1" rowspan="1">48,813 (74.1)</td><td align="left" colspan="1" rowspan="1">5,329 (77.1)</td><td align="left" colspan="1" rowspan="1">43,484 (73.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Housing status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Homeless</td><td align="left" colspan="1" rowspan="1">29,654 (45.0)</td><td align="left" colspan="1" rowspan="1">4,959 (71.8)</td><td align="left" colspan="1" rowspan="1">24,695 (41.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Housed</td><td align="left" colspan="1" rowspan="1">36,229 (55.0)</td><td align="left" colspan="1" rowspan="1">1,949 (28.2)</td><td align="left" colspan="1" rowspan="1">34,280 (58.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Co-occurring mental health diagnosis</td><td align="left" colspan="1" rowspan="1">48,719 (74.0)</td><td align="left" colspan="1" rowspan="1">6,039 (87.4)</td><td align="left" colspan="1" rowspan="1">42,680 (72.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Co-occurring substance use disorder diagnosis</td><td align="left" colspan="1" rowspan="1">33,053 (50.2)</td><td align="left" colspan="1" rowspan="1">5,579 (80.8)</td><td align="left" colspan="1" rowspan="1">27,474 (46.6)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Deyo co-morbidity index</td><td align="left" colspan="1" rowspan="1">7,737 (11.7)</td><td align="left" colspan="1" rowspan="1">402 (5.8)</td><td align="left" colspan="1" rowspan="1">7,335 (12.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">Service-connected disability rating</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">22,737 (34.5)</td><td align="left" colspan="1" rowspan="1">1,874 (27.1)</td><td align="left" colspan="1" rowspan="1">20,863 (35.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;50%</td><td align="left" colspan="1" rowspan="1">9,086 (13.8)</td><td align="left" colspan="1" rowspan="1">985 (14.3)</td><td align="left" colspan="1" rowspan="1">8,101 (13.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8805;50%</td><td align="left" colspan="1" rowspan="1">34,060 (51.7)</td><td align="left" colspan="1" rowspan="1">4,049 (58.6)</td><td align="left" colspan="1" rowspan="1">30,011 (50.9)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>SD&#8201;=&#8201;standard deviation</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Receipt of medications for opioid use disorder</title><p id="Par19">The overall raw rate of receipt of MOUD was 41.7%. The raw rate of receipt of MOUD by race/ethnicity, legal status, and the intersection of these characteristics is reported in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. For race/ethnicity, the rate of receipt ranged from 36.3% (<italic toggle="yes">n</italic>&#8201;=&#8201;315 of 867; 95% confidence interval [CI]&#8201;=&#8201;33.1&#8211;39.5%) for non-Hispanic American Indian/Alaskan Native veterans to 42.7% (<italic toggle="yes">n</italic>&#8201;=&#8201;1,661 of 3,887; 95% CI&#8201;=&#8201;41.2&#8211;44.3%) for Hispanic veterans. In the unadjusted logistic regression model, odds for receipt of MOUD was significantly lower for non-Hispanic Black veterans (odds ratio [OR]&#8201;=&#8201;0.63, 95% CI&#8201;=&#8201;0.59&#8211;0.68, <italic toggle="yes">p</italic>&#8201;&lt;.0001) compared to non-Hispanic White veterans. Veterans with legal involvement had higher odds of receipt of MOUD compared to Veterans without legal involvement (OR&#8201;=&#8201;1.35, 95% CI&#8201;=&#8201;1.18&#8211;1.55, <italic toggle="yes">p</italic>&#8201;&lt;.0001). The interaction effect indicated that non-Hispanic Black veterans with legal involvement (OR&#8201;=&#8201;0.74, 95% CI&#8201;=&#8201;0.65&#8211;0.84, <italic toggle="yes">p</italic>&#8201;&lt;.0001) and without legal involvement (OR&#8201;=&#8201;0.82, 95% CI&#8201;=&#8201;0.79&#8211;0.86, <italic toggle="yes">p</italic>&#8201;&lt;.0001) had lower odds of receipt of MOUD compared to non-Hispanic White veterans without legal involvement. Non-Hispanic Asian veterans with legal involvement (OR&#8201;=&#8201;1.67, 95% CI&#8201;=&#8201;1.09&#8211;2.56, <italic toggle="yes">p</italic>&#8201;=.02), Hispanic veterans with legal involvement (OR&#8201;=&#8201;1.41, 95% CI&#8201;=&#8201;1.15&#8211;1.72, <italic toggle="yes">p</italic>&#8201;=.001) and without legal involvement (OR&#8201;=&#8201;1.08, 95% CI&#8201;=&#8201;1.00-1.17, <italic toggle="yes">p</italic>&#8201;=.047), and non-Hispanic White veterans with legal involvement (OR&#8201;=&#8201;1.53, 95% CI&#8201;=&#8201;1.44&#8211;1.62, <italic toggle="yes">p</italic>&#8201;&lt;.0001) had higher odds of receipt of MOUD compared to non-Hispanic White veterans without legal involvement.</p><p id="Par20">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Receipt of medications for opioid use disorder among veterans in fiscal years 2021&#8211;2022</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Raw Rate of MOUD Receipt</th><th align="left" colspan="1" rowspan="1">Unadjusted MOUD<break/>Receipt</th><th align="left" colspan="1" rowspan="1">Adjusted MOUD Receipt</th><th align="left" colspan="1" rowspan="1">Predicted MOUD Receipt</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">n/N (%)<break/>[95% CI]</th><th align="left" colspan="1" rowspan="1">OR (95% CI)</th><th align="left" colspan="1" rowspan="1">AOR (95% CI)</th><th align="left" colspan="1" rowspan="1">Predicted Population Margin<break/>(95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Race/Ethnicity</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic American Indian/ Alaskan Native</td><td align="left" colspan="1" rowspan="1"><p>315/867 (36.3)</p><p>[33.1&#8211;39.5]</p></td><td align="left" colspan="1" rowspan="1"><p>0.83</p><p>(0.67&#8211;1.02)</p></td><td align="left" colspan="1" rowspan="1"><p>0.83</p><p>(0.66&#8211;1.02)</p></td><td align="left" colspan="1" rowspan="1"><p>38.3</p><p>(33.0-43.8)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Asian</td><td align="left" colspan="1" rowspan="1"><p>313/775 (40.4)</p><p>[36.9&#8211;43.8]</p></td><td align="left" colspan="1" rowspan="1"><p>1.00</p><p>(0.79&#8211;1.26)</p></td><td align="left" colspan="1" rowspan="1"><p>0.96</p><p>(0.76&#8211;1.21)</p></td><td align="left" colspan="1" rowspan="1"><p>41.9</p><p>(36.0&#8211;48.0)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1"><p>4,998/12,606 (39.6)</p><p>[38.8&#8211;40.5]</p></td><td align="left" colspan="1" rowspan="1"><p>0.63***</p><p>(0.59&#8211;0.68)</p></td><td align="left" colspan="1" rowspan="1"><p>0.78***</p><p>(0.72&#8211;0.84)</p></td><td align="left" colspan="1" rowspan="1"><p>36.9</p><p>(34.4&#8211;39.5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="left" colspan="1" rowspan="1"><p>1,661/3,887 (42.7)</p><p>[41.2&#8211;44.3]</p></td><td align="left" colspan="1" rowspan="1"><p>1.00</p><p>(0.89&#8211;1.12)</p></td><td align="left" colspan="1" rowspan="1"><p>0.96</p><p>(0.85&#8211;1.07)</p></td><td align="left" colspan="1" rowspan="1"><p>41.8</p><p>(38.5&#8211;45.2)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1"><p>20,189/47,748 (42.3)</p><p>[41.8&#8211;42.7]</p></td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1"><p>42.9</p><p>(40.7&#8211;45.1)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Legal status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;With legal involvement</td><td align="left" colspan="1" rowspan="1"><p>3,366/6,908 (48.7)</p><p>[47.5&#8211;49.9]</p></td><td align="left" colspan="1" rowspan="1"><p>1.35***</p><p>(1.18&#8211;1.55)</p></td><td align="left" colspan="1" rowspan="1"><p>0.98</p><p>(0.85&#8211;1.12)</p></td><td align="left" colspan="1" rowspan="1"><p>40.0</p><p>(36.4&#8211;43.8)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>24,110/58,975 (40.9)</p><p>[40.5&#8211;41.3]</p></td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1"><p>40.6</p><p>(38.3&#8211;43.0)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Race/Ethnicity * Legal status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic American Indian/ Alaskan Native * With legal involvement</td><td align="left" colspan="1" rowspan="1"><p>45/108 (41.7)</p><p>[32.4&#8211;51.0]</p></td><td align="left" colspan="1" rowspan="1"><p>1.20</p><p>(0.81&#8211;1.78)</p></td><td align="left" colspan="1" rowspan="1"><p>0.86</p><p>(0.57&#8211;1.28)</p></td><td align="left" colspan="1" rowspan="1"><p>38.3</p><p>(29.3&#8211;48.3)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Asian * With legal involvement</td><td align="left" colspan="1" rowspan="1"><p>46/88 (52.3)</p><p>[41.8&#8211;62.7]</p></td><td align="left" colspan="1" rowspan="1"><p>1.67*</p><p>(1.09&#8211;2.56)</p></td><td align="left" colspan="1" rowspan="1"><p>1.12</p><p>(0.72&#8211;1.73)</p></td><td align="left" colspan="1" rowspan="1"><p>44.8</p><p>(34.2&#8211;55.8)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black &amp; With legal involvement</td><td align="left" colspan="1" rowspan="1"><p>420/1,156 (36.3)</p><p>[33.6&#8211;39.1]</p></td><td align="left" colspan="1" rowspan="1"><p>0.74***</p><p>(0.65&#8211;0.84)</p></td><td align="left" colspan="1" rowspan="1"><p>0.67***</p><p>(0.59&#8211;0.77)</p></td><td align="left" colspan="1" rowspan="1"><p>32.9</p><p>(29.6&#8211;36.3)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic &amp; with legal involvement</td><td align="left" colspan="1" rowspan="1"><p>193/403 (47.9)</p><p>[33.6&#8211;52.8]</p></td><td align="left" colspan="1" rowspan="1"><p>1.41*</p><p>(1.15&#8211;1.72)</p></td><td align="left" colspan="1" rowspan="1"><p>0.95</p><p>(0.77&#8211;1.17)</p></td><td align="left" colspan="1" rowspan="1"><p>40.9</p><p>(35.6&#8211;46.3)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White * With legal involvement</td><td align="left" colspan="1" rowspan="1"><p>2,662/5,153 (51.7)</p><p>[50.3&#8211;53.0]</p></td><td align="left" colspan="1" rowspan="1"><p>1.53***</p><p>(1.44&#8211;1.62)</p></td><td align="left" colspan="1" rowspan="1"><p>1.07*</p><p>(1.01&#8211;1.14)</p></td><td align="left" colspan="1" rowspan="1"><p>43.7</p><p>(41.2&#8211;46.3)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic American Indian/ Alaskan Native * Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>270/759 (35.6)</p><p>[32.2&#8211;39.0]</p></td><td align="left" colspan="1" rowspan="1"><p>0.87</p><p>(0.74&#8211;1.01)</p></td><td align="left" colspan="1" rowspan="1"><p>0.85*</p><p>(0.73&#8211;0.99)</p></td><td align="left" colspan="1" rowspan="1"><p>38.2</p><p>(34.1&#8211;42.5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Non-Hispanic Asian * Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>267/687 (38.9)</p><p>[35.2&#8211;42.5]</p></td><td align="left" colspan="1" rowspan="1"><p>0.92</p><p>(0.78&#8211;1.07)</p></td><td align="left" colspan="1" rowspan="1"><p>0.88</p><p>(0.75&#8211;1.04)</p></td><td align="left" colspan="1" rowspan="1"><p>39.0</p><p>(34.8&#8211;43.4)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black * Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>4,578/11,450 (40.0)</p><p>[39.1&#8211;40.9]</p></td><td align="left" colspan="1" rowspan="1"><p>0.82***</p><p>(0.79&#8211;0.86)</p></td><td align="left" colspan="1" rowspan="1"><p>0.96</p><p>(0.92&#8211;1.01)</p></td><td align="left" colspan="1" rowspan="1"><p>41.1</p><p>(38.8&#8211;43.5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic &amp; Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>1,468/3,484 (42.1)</p><p>[40.5&#8211;43.8]</p></td><td align="left" colspan="1" rowspan="1"><p>1.08*</p><p>(1.00-1.17)</p></td><td align="left" colspan="1" rowspan="1"><p>1.03</p><p>(0.95&#8211;1.11)</p></td><td align="left" colspan="1" rowspan="1"><p>42.8</p><p>(40.0-45.6)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White * Without legal involvement</td><td align="left" colspan="1" rowspan="1"><p>17,527/42,595 (41.1)</p><p>[40.7&#8211;41.6]</p></td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1">Ref</td><td align="left" colspan="1" rowspan="1"><p>42.1</p><p>(39.9&#8211;42.2)</p></td></tr></tbody></table><table-wrap-foot><p>MOUD&#8201;=&#8201;medications for opioid use disorder. OR&#8201;=&#8201;odds ratio. CI&#8201;=&#8201;confidence interval. AOR&#8201;=&#8201;adjusted odds ratio</p><p>*<italic toggle="yes">p</italic>&#8201;&lt;.05. ***<italic toggle="yes">p</italic>&#8201;&lt;.001</p></table-wrap-foot></table-wrap>
</p><p id="Par21">The adjusted logistic regression model of MOUD receipt by race and legal status, controlling for patient and facility characteristics, is reported in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Odds of receipt of MOUD was significantly lower for non-Hispanic Black patients compared to non-Hispanic White patients (adjusted odds ratio [AOR]&#8201;=&#8201;0.78, 95% CI&#8201;=&#8201;0.72&#8211;0.84, <italic toggle="yes">p</italic>&#8201;&lt;.0001). The interaction effect indicated that non-Hispanic Black patients with legal involvement (AOR&#8201;=&#8201;0.67, 95% CI&#8201;=&#8201;0.59&#8211;0.77, <italic toggle="yes">p</italic>&#8201;&lt;.0001) had lower odds of MOUD receipt compared to the reference group of non-Hispanic White patients without legal involvement. Non-Hispanic American Indian/Alaskan Native veterans without legal involvement also had lower odds of receipt of MOUD compared to non-Hispanic White veterans without legal involvement (AOR&#8201;=&#8201;0.85, 95% CI&#8201;=&#8201;0.73&#8211;0.99, <italic toggle="yes">p</italic>&#8201;=.04). Non-Hispanic White veterans with legal involvement had higher odds of receipt of MOUD compared to non-Hispanic White veterans without legal involvement (AOR&#8201;=&#8201;1.07, 95% CI&#8201;=&#8201;1.01&#8211;1.14, <italic toggle="yes">p</italic>&#8201;=.03).</p><p id="Par22">The predicted population margin of MOUD receipt and 95% confidence intervals by race and legal status are reported in Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and displayed in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The predicted population margin of MOUD receipt for non-Hispanic Black veterans with legal involvement was 32.9% (95% CI&#8201;=&#8201;29.6&#8211;36.3%), for non-Hispanic American Indian Alaskan Native veterans without legal involvement was 38.2% (95% CI&#8201;=&#8201;34.1&#8211;42.5%), for non-Hispanic White veterans with legal involvement was 43.7% (95% CI&#8201;=&#8201;41.2&#8211;46.3%), and for non-Hispanic White patients without legal involvement was 42.1% (95% CI&#8201;=&#8201;39.9&#8211;44.2%).</p><p id="Par23">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Predicted population margin of medications for opioid use disorder receipt by race/ethnicity and legal status </p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1209" position="float" orientation="portrait" xlink:href="40352_2025_336_Fig1_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec9"><title>Discussion</title><p id="Par24">In a large national sample of veterans served at the VHA in Fiscal Years 2021&#8211;2022, non-Hispanic Black patients with legal involvement had lower odds of receiving MOUD compared to non-Hispanic White patients without legal involvement. These results suggest that for Black veterans, the interaction of racial/ethnic minority status and legal involvement can impact medication receipt. Results also indicated that non-Hispanic American Indian/Alaskan Native veterans without legal involvement had lower odds of receiving MOUD compared to non-Hispanic White patients without legal involvement. Interventions that target both racial and criminal legal barriers are needed.</p><p id="Par25">Structural factors have been identified as barriers to MOUD for both legal involved and different racial/ethnically populations and may partially explain why Black veterans with legal involvement have the lowest receipt of MOUD. For example, Black people in the United States more frequently experience criminalization of opioid use compared to White people, and drug enforcement more commonly occurs in Black communities (James &amp; Jordan, <xref ref-type="bibr" rid="CR24">2018</xref>), which may deter Black patients from seeking treatment and/or limit treatment access. Furthermore, Black people arrested for drug related charges have lower odds of being referred to, initiating, and graduating from a drug court than White people (Ho et al., <xref ref-type="bibr" rid="CR21">2018</xref>; Nicosia et al., <xref ref-type="bibr" rid="CR31">2013</xref>), suggesting Black people may have fewer opportunities to learn about or connect with treatment within legal contexts than White people and may be incarcerated more often limiting their ability to seek treatment at a VHA medical center. Although we do not have information on whether veterans in this study received medication during their incarceration, MOUD availability in prisons and jails is limited (Scott et al., <xref ref-type="bibr" rid="CR39">2021</xref>; Sufrin et al., <xref ref-type="bibr" rid="CR40">2023</xref>), which is a missed opportunity to educate about and initiate these medications for patients for whom it is indicated, particularly veterans from groups who are disproportionately incarcerated (Tsai et al., <xref ref-type="bibr" rid="CR42">2013</xref>). Even when MOUD is provided in carceral settings, White individuals are more likely to receive MOUD in jails than individuals from other racial and ethnic groups (The Commonwealth of Massachusetts, <xref ref-type="bibr" rid="CR41">2024</xref>).</p><p id="Par26">The VHA may contribute to these structural factors through a lack of available services in geographic areas that serve more Black veterans or through policies, such as not honoring prison or jail prescriptions for MOUD for veterans who exit incarceration. Connecting patients to MOUD while in correctional settings increased treatment entry post-incarceration (Marsden et al., <xref ref-type="bibr" rid="CR30">2017</xref>), but care coordination between these settings and VHA is unknown. While there have been ongoing, successful efforts to improve prescribing of MOUD at the VHA (Hagedorn et al., <xref ref-type="bibr" rid="CR17">2022</xref>; Wyse et al., <xref ref-type="bibr" rid="CR45">2018</xref>), implementation efforts could inadvertently exacerbate or prolong differences in access if racial or criminal legal factors are not considered. Qualitive research, such as narrative stories (Mark et al., <xref ref-type="bibr" rid="CR29">2023</xref>), with Black veterans with legal involvement may shed light on why they have lower odds of receiving MOUD than their White veterans with legal involvement. Within the VHA, there is an effort to expand existing dashboards to monitor provision of MOUD by various patient factors may allow providers at each VHA to identify patients who would benefit from but are not utilizing MOUD. However, these dashboards would need to account for uncertainty due to small groups. A dashboard to successfully reduce racial differences in blood pressure control is one potential model that could also be used for patients who need MOUD (Burkitt et al., <xref ref-type="bibr" rid="CR6">2021</xref>).</p><p id="Par27">Stigma and preferences for certain medications, both in the criminal legal system and in the healthcare system may limit available MOUD options (Andraka-Christou, <xref ref-type="bibr" rid="CR1">2021</xref>; Andraka-Christou et al., <xref ref-type="bibr" rid="CR2">2019</xref>; Hansen &amp; Roberts, <xref ref-type="bibr" rid="CR19">2012</xref>; Lagisetty et al., <xref ref-type="bibr" rid="CR27">2019</xref>; Sufrin et al., <xref ref-type="bibr" rid="CR40">2023</xref>). Buprenorphine, which is more convenient than methadone, is less often prescribed to Black patients compared to White patients (Lagisetty et al., <xref ref-type="bibr" rid="CR27">2019</xref>). Federal regulatory differences between methadone and buprenorphine were driven by racial/ethnic associations (Hansen &amp; Roberts, <xref ref-type="bibr" rid="CR19">2012</xref>). Practices that may reduce racial differences in MOUD include allowing office-based methadone without extensive regulatory barriers, increasing MOUD availability in primary care settings through a pharmacist care manager model, and improving permanent retention of remote buprenorphine induction via telehealth (Andraka-Christou, <xref ref-type="bibr" rid="CR1">2021</xref>; DeRonne et al., <xref ref-type="bibr" rid="CR10">2021</xref>). Criminal legal staff and healthcare provider training that addresses stigma associated with MOUD and race/ethnicity or legal involvement may also help improve gaps in medication receipt.</p><p id="Par28">Interpersonal, systemic, and structural factors related to race may play a role in medication receipt (Braveman et al., <xref ref-type="bibr" rid="CR5">2022</xref>). Perceptions of an untrustworthy healthcare system, fewer race-concordant providers, and perceived discrimination from healthcare providers (Cuevas et al., <xref ref-type="bibr" rid="CR8">2016</xref>; King &amp; Redwood, <xref ref-type="bibr" rid="CR25">2016</xref>; Saha et al., <xref ref-type="bibr" rid="CR36">2008</xref>) may result in Black patients seeking less care. Addressing differences in receipt of MOUD among non-Hispanic Black patients is especially critical because of the exponential growth in overdose rates among Black people (Jalal et al., <xref ref-type="bibr" rid="CR23">2018</xref>; Saloner et al., <xref ref-type="bibr" rid="CR37">2018</xref>). Non-Hispanic American Indian/Alaskan Native veterans without legal involvement also experienced a lower predicted population margin of MOUD receipt compared to non-Hispanic White veterans without legal involvement. Prior research with a general population sample indicates that patients who received methadone had higher odds of experiencing racial discrimination in a healthcare setting and that the odds of racial discrimination were especially pronounced among American Indian/Alaskan Native and Black patients (Pro &amp; Zaller, <xref ref-type="bibr" rid="CR33">2020</xref>). Targeted and culturally appropriate outreach, particularly outreach conducted by peers (Giraldo et al., <xref ref-type="bibr" rid="CR16">2024</xref>), may address some of the perceptions Black veterans may have in seeking healthcare.</p></sec><sec id="Sec10"><title>Limitations</title><p id="Par29">There were a few limitations to this study. First, MOUD that is accessed in non-VHA settings and paid for by the VHA are recorded in VHA data, but we have no ability to identify how many patients may seek care outside the VHA system that is not paid for by the VHA. Uncaptured treatment use may account for some of the differences we observed, such as use of non-VHA healthcare as a result of Medicaid expansion (Winkelman et al., <xref ref-type="bibr" rid="CR44">2016</xref>). Second, any patients with a record of being Hispanic were coded as Hispanic, regardless of race. Third, we were not able to determine if and where veterans were offered MOUD. Although prescription records indicate buprenorphine and naltrexone were offered at all facilities, we are unable to determine if all providers offer these medications or whether veterans received MOUD prior to their VHA treatment, such as during prison or jail incarceration. Finally, our legal involvement and race/ethnicity measures are limited. We cannot identify veterans who were reached out to by a Veterans Justice Programs staff member but did not respond or were unidentified as veterans in criminal legal settings; therefore, some veterans in the no legal involvement group may have had legal involvement. Furthermore, we do not have detailed information on veterans&#8217; experiences with the legal system, such as the nature and severity of a veteran&#8217;s crime. Finally, we do not have other measures of race/ethnicity, such as perceived discrimination or implicit bias. Such measures could deepen our understanding of challenges patients experience in accessing MOUD (Mark et al., <xref ref-type="bibr" rid="CR29">2023</xref>).</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par30">In this study, we provide evidence that differences in MOUD receipt are borne disproportionately by non-Hispanic Black veterans with legal involvement. VHA dashboards that stratify by various forms of marginalization may help to identify veterans who are not receiving MOUD. Interventions in specific criminal justice settings and efforts to reduce patient, clinical, and regulatory barriers to access may be needed to improve medication receipt among Black veterans with legal involvement.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>AKF contributed to the Conceptualization, Data Curation, Funding acquisition, Methodology, Project administration, Resources, Supervision, and Writing-original draft. EP contributed to the Conceptualization, and Writing-original draft. MY contributed to the Data Curation, Formal analysis, Methodology, Visualization, and Writing-review and editing. CT, IAB, and DS contributed to the Conceptualization, Funding acquisition, Methodology, and Writing-review and editing. ET contributed to the Project administration and Writing-original draft. AHSH contributed to the Conceptualization, Funding acquisition, Methodology, Visualization, and Writing-original draft. All authors approved the submitted version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Research reported in this publication was supported by the Department of Veterans Affairs (VA) Health Services Research &amp; Development (HSR&amp;D) Merit Awards (IIR 16&#8211;239; IIR 20&#8211;040). Dr. Pivovarova was supported by the National Institute on Drug Abuse (NIDA K23 DA049953). Dr. Timko was supported by a VA HSR&amp;D Senior Research Career Scientist award (RCS 00&#8211;001). Dr. Harris was supported by a VA HSR&amp;D Research Career Scientist award (RCS 14&#8211;232). The VA and National Institutes of Health had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position nor policy of the Department of Veterans Affairs (VA) or the United States government or the National Institutes of Health or Kaiser Permanente.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data cannot be shared publicly because of VA policies regarding data privacy and security. Data contain potentially identifying and sensitive patient information.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par31">This study was approved by the Stanford University Institutional Review Board (#44494) and the VA Palo Alto Research &amp; Development Committee in accordance with the Declaration of Helsinki. All data reported in this manuscript were approved under a waiver of consent.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par32">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>AOR</term><def><p id="Par33">Adjusted Odds Ratio</p></def></def-item><def-item><term>MOUD</term><def><p id="Par34">Medications for Opioid Use Disorder</p></def></def-item><def-item><term>OR</term><def><p id="Par35">Odds Ratio</p></def></def-item><def-item><term>US</term><def><p id="Par36">United States</p></def></def-item><def-item><term>VA</term><def><p id="Par37">Veterans Affairs</p></def></def-item><def-item><term>VHA</term><def><p id="Par38">Veterans Health Administration</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></name></person-group><article-title>Addressing Racial and ethnic disparities in the use of medications for opioid use disorder</article-title><source>Health Affairs</source><year>2021</year><volume>40</volume><issue>6</issue><fpage>920</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2020.02261</pub-id><pub-id pub-id-type="pmid">34097509</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Andraka-Christou, B. (2021). Addressing Racial and ethnic disparities in the use of medications for opioid use disorder. <italic toggle="yes">Health Affairs</italic>, <italic toggle="yes">40</italic>(6), 920&#8211;927. 10.1377/hlthaff.2020.02261<pub-id pub-id-type="pmid">34097509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2020.02261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andraka-Christou</surname><given-names>B</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>M</given-names></name><name name-style="western"><surname>Madeira</surname><given-names>J</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>RD</given-names></name></person-group><article-title>Court personnel attitudes towards medication-assisted treatment: A state-wide survey</article-title><source>Journal of Substance Abuse Treatment</source><year>2019</year><volume>104</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.06.011</pub-id><pub-id pub-id-type="pmid">31370988</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Andraka-Christou, B., Gabriel, M., Madeira, J., &amp; Silverman, R. D. (2019). Court personnel attitudes towards medication-assisted treatment: A state-wide survey. <italic toggle="yes">Journal of Substance Abuse Treatment</italic>, <italic toggle="yes">104</italic>, 72&#8211;82. 10.1016/j.jsat.2019.06.011<pub-id pub-id-type="pmid">31370988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2019.06.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berk</surname><given-names>J</given-names></name><name name-style="western"><surname>Brar</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoadley</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R</given-names></name></person-group><article-title>Racial differences in medications for opioid use disorder initiation in a carceral setting</article-title><source>Substance Use &amp; Addiction Journal</source><year>2025</year><volume>46</volume><issue>1</issue><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1177/29767342241273417</pub-id><pub-id pub-id-type="pmid">39219484</pub-id><pub-id pub-id-type="pmcid">PMC11979573</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Berk, J., Brar, J., Hoadley, A., &amp; Martin, R. (2025). Racial differences in medications for opioid use disorder initiation in a carceral setting. <italic toggle="yes">Substance Use &amp; Addiction Journal</italic>, <italic toggle="yes">46</italic>(1), 64&#8211;71. 10.1177/29767342241273417<pub-id pub-id-type="pmid">39219484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/29767342241273417</pub-id><pub-id pub-id-type="pmcid">PMC11979573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blue-Howells</surname><given-names>JH</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SC</given-names></name><name name-style="western"><surname>van den Berk-Clark</surname><given-names>C</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>JF</given-names></name></person-group><article-title>The U.S. Department of veterans affairs veterans justice programs and the sequential intercept model: Case examples in National dissemination of intervention for justice-involved veterans</article-title><source>Psychological Services</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1037/a0029652</pub-id><pub-id pub-id-type="pmid">22924802</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Blue-Howells, J. H., Clark, S. C., van den Berk-Clark, C., &amp; McGuire, J. F. (2013). The U.S. Department of veterans affairs veterans justice programs and the sequential intercept model: Case examples in National dissemination of intervention for justice-involved veterans. <italic toggle="yes">Psychological Services</italic>, <italic toggle="yes">10</italic>(1), 48&#8211;53. 10.1037/a0029652<pub-id pub-id-type="pmid">22924802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/a0029652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braveman</surname><given-names>PA</given-names></name><name name-style="western"><surname>Arkin</surname><given-names>E</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>D</given-names></name><name name-style="western"><surname>Kauh</surname><given-names>T</given-names></name><name name-style="western"><surname>Holm</surname><given-names>N</given-names></name></person-group><article-title>Systemic and structural racism: Definitions, examples, health damages, and approaches to dismantling</article-title><source>Health Affairs</source><year>2022</year><volume>41</volume><issue>2</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2021.01394</pub-id><pub-id pub-id-type="pmid">35130057</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Braveman, P. A., Arkin, E., Proctor, D., Kauh, T., &amp; Holm, N. (2022). Systemic and structural racism: Definitions, examples, health damages, and approaches to dismantling. <italic toggle="yes">Health Affairs</italic>, <italic toggle="yes">41</italic>(2), 171&#8211;178. 10.1377/hlthaff.2021.01394<pub-id pub-id-type="pmid">35130057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2021.01394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkitt</surname><given-names>KH</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>KL</given-names></name><name name-style="western"><surname>Mor</surname><given-names>MK</given-names></name><name name-style="western"><surname>Fine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Macpherson</surname><given-names>DS</given-names></name><name name-style="western"><surname>Mannozzi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Muldoon</surname><given-names>MF</given-names></name><name name-style="western"><surname>Long</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hausmann</surname><given-names>LRM</given-names></name></person-group><article-title>Evaluation of a collaborative VA network initiative to reduce Racial disparities in blood pressure control among veterans with severe hypertension</article-title><source>Healthcare</source><year>2021</year><volume>8</volume><issue>Suppl 1</issue><fpage>100485</fpage><pub-id pub-id-type="doi">10.1016/j.hjdsi.2020.100485</pub-id><pub-id pub-id-type="pmid">34175098</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Burkitt, K. H., Rodriguez, K. L., Mor, M. K., Fine, M. J., Clark, W. J., Macpherson, D. S., Mannozzi, C. M., Muldoon, M. F., Long, J. A., &amp; Hausmann, L. R. M. (2021). Evaluation of a collaborative VA network initiative to reduce Racial disparities in blood pressure control among veterans with severe hypertension. <italic toggle="yes">Healthcare</italic>, <italic toggle="yes">8</italic>(Suppl 1), 100485. 10.1016/j.hjdsi.2020.100485<pub-id pub-id-type="pmid">34175098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hjdsi.2020.100485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><mixed-citation publication-type="other">Center for Medicaid and CHIP Services, Centers for Medicare &amp; Medicaid Services (2022). <italic toggle="yes">Core set of adult health care quality measures for Medicaid: Technical specifications and resource manual for federal Fiscal Year 2022 reporting</italic>. Authors. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medicaid.gov/medicaid/quality-of-care/downloads/medicaid-adult-core-set-manual.pdf?t=1656605214">https://www.medicaid.gov/medicaid/quality-of-care/downloads/medicaid-adult-core-set-manual.pdf?t=1656605214</ext-link></mixed-citation></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuevas</surname><given-names>AG</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name></person-group><article-title>African American experiences in healthcare: I always feel like i&#8217;m getting skipped over</article-title><source>Health Psychology</source><year>2016</year><volume>35</volume><issue>9</issue><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1037/hea0000368</pub-id><pub-id pub-id-type="pmid">27175576</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Cuevas, A. G., O&#8217;Brien, K., &amp; Saha, S. (2016). African American experiences in healthcare: I always feel like i&#8217;m getting skipped over. <italic toggle="yes">Health Psychology</italic>, <italic toggle="yes">35</italic>(9), 987&#8211;995. 10.1037/hea0000368<pub-id pub-id-type="pmid">27175576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/hea0000368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><mixed-citation publication-type="other">Department of Veterans Affairs &amp; Department of Defense. (2021). <italic toggle="yes">VA/DoD clinical practice guideline for the management of substance use disorders</italic>. Authors.</mixed-citation></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeRonne</surname><given-names>BM</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KR</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>E</given-names></name><name name-style="western"><surname>Jones</surname><given-names>E</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>EE</given-names></name></person-group><article-title>Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder</article-title><source>American Journal of Health-System Pharmacy</source><year>2021</year><volume>78</volume><issue>4</issue><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1093/ajhp/zxaa405</pub-id><pub-id pub-id-type="pmid">33326564</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">DeRonne, B. M., Wong, K. R., Schultz, E., Jones, E., &amp; Krebs, E. E. (2021). Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder. <italic toggle="yes">American Journal of Health-System Pharmacy</italic>, <italic toggle="yes">78</italic>(4), 354&#8211;359. 10.1093/ajhp/zxaa405<pub-id pub-id-type="pmid">33326564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajhp/zxaa405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deyo</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cherkin</surname><given-names>DC</given-names></name><name name-style="western"><surname>Ciol</surname><given-names>MA</given-names></name></person-group><article-title>Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases</article-title><source>Journal of Clinical Epidemiology</source><year>1992</year><volume>45</volume><issue>6</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(92)90133-8</pub-id><pub-id pub-id-type="pmid">1607900</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Deyo, R. A., Cherkin, D. C., &amp; Ciol, M. A. (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. <italic toggle="yes">Journal of Clinical Epidemiology</italic>, <italic toggle="yes">45</italic>(6), 613&#8211;619.<pub-id pub-id-type="pmid">1607900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0895-4356(92)90133-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>AK</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>J</given-names></name><name name-style="western"><surname>Blue-Howells</surname><given-names>J</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>J</given-names></name><name name-style="western"><surname>Timko</surname><given-names>C</given-names></name><name name-style="western"><surname>Frayne</surname><given-names>SM</given-names></name><name name-style="western"><surname>Smelson</surname><given-names>D</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>E</given-names></name><name name-style="western"><surname>Binswanger</surname><given-names>I</given-names></name></person-group><article-title>Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans health administration patients</article-title><source>Drug and Alcohol Dependence</source><year>2016</year><volume>160</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.01.013</pub-id><pub-id pub-id-type="pmid">26832998</pub-id><pub-id pub-id-type="pmcid">PMC4767599</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Finlay, A. K., Harris, A. H. S., Rosenthal, J., Blue-Howells, J., Clark, S., McGuire, J., Timko, C., Frayne, S. M., Smelson, D., Oliva, E., &amp; Binswanger, I. (2016a). Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans health administration patients. <italic toggle="yes">Drug and Alcohol Dependence</italic>, <italic toggle="yes">160</italic>, 222&#8211;226. 10.1016/j.drugalcdep.2016.01.013<pub-id pub-id-type="pmid">26832998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2016.01.013</pub-id><pub-id pub-id-type="pmcid">PMC4767599</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>AK</given-names></name><name name-style="western"><surname>Smelson</surname><given-names>D</given-names></name><name name-style="western"><surname>Sawh</surname><given-names>L</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>J</given-names></name><name name-style="western"><surname>Blue-Howells</surname><given-names>J</given-names></name><name name-style="western"><surname>Timko</surname><given-names>C</given-names></name><name name-style="western"><surname>Binswanger</surname><given-names>I</given-names></name><name name-style="western"><surname>Frayne</surname><given-names>SM</given-names></name><name name-style="western"><surname>Blodgett</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bowe</surname><given-names>T</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SC</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name></person-group><article-title>U.S. Department of veterans affairs veterans justice outreach program: Connecting justice-involved veterans with mental health and substance use disorder treatment</article-title><source>Criminal Justice Policy Review</source><year>2016</year><volume>27</volume><issue>2</issue><fpage>203</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1177/0887403414562601</pub-id><pub-id pub-id-type="pmcid">PMC7073452</pub-id><pub-id pub-id-type="pmid">32180665</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Finlay, A. K., Smelson, D., Sawh, L., McGuire, J., Rosenthal, J., Blue-Howells, J., Timko, C., Binswanger, I., Frayne, S. M., Blodgett, J. C., Bowe, T., Clark, S. C., &amp; Harris, A. H. S. (2016b). U.S. Department of veterans affairs veterans justice outreach program: Connecting justice-involved veterans with mental health and substance use disorder treatment. <italic toggle="yes">Criminal Justice Policy Review</italic>, <italic toggle="yes">27</italic>(2), 203&#8211;222. 10.1177/0887403414562601<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0887403414562601</pub-id><pub-id pub-id-type="pmcid">PMC7073452</pub-id><pub-id pub-id-type="pmid">32180665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>AK</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Timko</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Smelson</surname><given-names>D</given-names></name><name name-style="western"><surname>Stimmel</surname><given-names>M</given-names></name><name name-style="western"><surname>Binswanger</surname><given-names>IA</given-names></name></person-group><article-title>Disparities in access to medications for opioid use disorder in the veterans health administration</article-title><source>Journal of Addiction Medicine</source><year>2021</year><volume>15</volume><issue>2</issue><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000719</pub-id><pub-id pub-id-type="pmid">32826617</pub-id><pub-id pub-id-type="pmcid">PMC7889740</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Finlay, A. K., Harris, A. H. S., Timko, C., Yu, M., Smelson, D., Stimmel, M., &amp; Binswanger, I. A. (2021). Disparities in access to medications for opioid use disorder in the veterans health administration. <italic toggle="yes">Journal of Addiction Medicine</italic>, <italic toggle="yes">15</italic>(2), 143&#8211;149. 10.1097/ADM.0000000000000719<pub-id pub-id-type="pmid">32826617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000719</pub-id><pub-id pub-id-type="pmcid">PMC7889740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>AK</given-names></name><name name-style="western"><surname>Palframan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Stimmel</surname><given-names>M</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>JF</given-names></name></person-group><article-title>Legal system involvement and opioid-related overdose mortality in U.S. Department of veterans affairs patients</article-title><source>American Journal of Preventive Medicine</source><year>2022</year><volume>62</volume><issue>1</issue><fpage>e29</fpage><lpage>e37</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2021.06.014</pub-id><pub-id pub-id-type="pmid">34521559</pub-id><pub-id pub-id-type="pmcid">PMC8849578</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Finlay, A. K., Palframan, K. M., Stimmel, M., &amp; McCarthy, J. F. (2022). Legal system involvement and opioid-related overdose mortality in U.S. Department of veterans affairs patients. <italic toggle="yes">American Journal of Preventive Medicine</italic>, <italic toggle="yes">62</italic>(1), e29&#8211;e37. 10.1016/j.amepre.2021.06.014<pub-id pub-id-type="pmid">34521559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2021.06.014</pub-id><pub-id pub-id-type="pmcid">PMC8849578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giraldo</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P</given-names></name><name name-style="western"><surname>Zerbo</surname><given-names>E</given-names></name><name name-style="western"><surname>Nyaku</surname><given-names>AN</given-names></name></person-group><article-title>The role of recovery peer navigators in retention in outpatient buprenorphine treatment: A retrospective cohort study</article-title><source>Annals of Medicine</source><year>2024</year><volume>56</volume><issue>1</issue><fpage>2355566</fpage><pub-id pub-id-type="doi">10.1080/07853890.2024.2355566</pub-id><pub-id pub-id-type="pmid">38823420</pub-id><pub-id pub-id-type="pmcid">PMC11146239</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Giraldo, A., Shah, P., Zerbo, E., &amp; Nyaku, A. N. (2024). The role of recovery peer navigators in retention in outpatient buprenorphine treatment: A retrospective cohort study. <italic toggle="yes">Annals of Medicine</italic>, <italic toggle="yes">56</italic>(1), 2355566. 10.1080/07853890.2024.2355566<pub-id pub-id-type="pmid">38823420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2024.2355566</pub-id><pub-id pub-id-type="pmcid">PMC11146239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagedorn</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Gustavson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ackland</surname><given-names>PE</given-names></name><name name-style="western"><surname>Bangerter</surname><given-names>A</given-names></name><name name-style="western"><surname>Bounthavong</surname><given-names>M</given-names></name><name name-style="western"><surname>Clothier</surname><given-names>B</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>ME</given-names></name><name name-style="western"><surname>Noorbaloochi</surname><given-names>S</given-names></name><name name-style="western"><surname>Salameh</surname><given-names>HA</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name></person-group><article-title>Advancing Pharmacological treatments for opioid use disorder (ADaPT-OUD): An implementation trial in eight veterans health administration facilities</article-title><source>Journal of General Internal Medicine</source><year>2022</year><volume>37</volume><issue>14</issue><fpage>3594</fpage><lpage>3602</lpage><pub-id pub-id-type="doi">10.1007/s11606-021-07274-7</pub-id><pub-id pub-id-type="pmid">34981352</pub-id><pub-id pub-id-type="pmcid">PMC8722660</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hagedorn, H. J., Gustavson, A. M., Ackland, P. E., Bangerter, A., Bounthavong, M., Clothier, B., Harris, A. H. S., Kenny, M. E., Noorbaloochi, S., Salameh, H. A., &amp; Gordon, A. J. (2022). Advancing Pharmacological treatments for opioid use disorder (ADaPT-OUD): An implementation trial in eight veterans health administration facilities. <italic toggle="yes">Journal of General Internal Medicine</italic>, <italic toggle="yes">37</italic>(14), 3594&#8211;3602. 10.1007/s11606-021-07274-7<pub-id pub-id-type="pmid">34981352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-021-07274-7</pub-id><pub-id pub-id-type="pmcid">PMC8722660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Cotto</surname><given-names>J</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Racial and ethnic disparities in drug overdose deaths in the US during the COVID-19 pandemic</article-title><source>JAMA Network Open</source><year>2022</year><volume>5</volume><issue>9</issue><fpage>e2232314</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.32314</pub-id><pub-id pub-id-type="pmid">36125815</pub-id><pub-id pub-id-type="pmcid">PMC9490498</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Han, B., Einstein, E. B., Jones, C. M., Cotto, J., Compton, W. M., &amp; Volkow, N. D. (2022). Racial and ethnic disparities in drug overdose deaths in the US during the COVID-19 pandemic. <italic toggle="yes">JAMA Network Open</italic>, <italic toggle="yes">5</italic>(9), e2232314. 10.1001/jamanetworkopen.2022.32314<pub-id pub-id-type="pmid">36125815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.32314</pub-id><pub-id pub-id-type="pmcid">PMC9490498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><mixed-citation publication-type="other">Hansen, H. B., &amp; Roberts, S. K. (2012). Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. In J. Netherland (Ed.), <italic toggle="yes">Critical perspectives on addiction</italic><italic toggle="yes">14</italic>, pp. 79&#8211;102). Emerald Group Publishing Limited. 10.1108/S1057-6290(2012)0000014008</mixed-citation></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Weisner</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Capoccia</surname><given-names>V</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>CP</given-names></name></person-group><article-title>Specifying and pilot testing quality measures for the American society of addiction medicine&#8217;s standards of care</article-title><source>Journal of Addiction Medicine</source><year>2016</year><volume>10</volume><issue>3</issue><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000203</pub-id><pub-id pub-id-type="pmid">26933875</pub-id><pub-id pub-id-type="pmcid">PMC5001552</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Harris, A. H. S., Weisner, C. M., Chalk, M., Capoccia, V., Chen, C., &amp; Thomas, C. P. (2016). Specifying and pilot testing quality measures for the American society of addiction medicine&#8217;s standards of care. <italic toggle="yes">Journal of Addiction Medicine</italic>, <italic toggle="yes">10</italic>(3), 148&#8211;155. 10.1097/ADM.0000000000000203<pub-id pub-id-type="pmid">26933875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000203</pub-id><pub-id pub-id-type="pmcid">PMC5001552</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>T</given-names></name><name name-style="western"><surname>Carey</surname><given-names>SM</given-names></name><name name-style="western"><surname>Malsch</surname><given-names>AM</given-names></name></person-group><article-title>Racial and gender disparities in treatment courts: Do they exist and is there anything we can do to change them?</article-title><source>Journal for Advancing Justice</source><year>2018</year><volume>I</volume><fpage>5</fpage><lpage>34</lpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ho, T., Carey, S. M., &amp; Malsch, A. M. (2018). Racial and gender disparities in treatment courts: Do they exist and is there anything we can do to change them? <italic toggle="yes">Journal for Advancing Justice</italic>, <italic toggle="yes">I</italic>, 5&#8211;34.</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cromartie</surname><given-names>D</given-names></name><name name-style="western"><surname>Fitzelle-Jones</surname><given-names>E</given-names></name><name name-style="western"><surname>Brochier</surname><given-names>A</given-names></name><name name-style="western"><surname>Borba</surname><given-names>CPC</given-names></name><name name-style="western"><surname>Montalvo</surname><given-names>C</given-names></name></person-group><article-title>A qualitative analysis of barriers to opioid agonist treatment for Racial/ethnic minoritized populations</article-title><source>Journal of Substance Abuse Treatment</source><year>2023</year><volume>144</volume><fpage>108918</fpage><pub-id pub-id-type="doi">10.1016/j.jsat.2022.108918</pub-id><pub-id pub-id-type="pmid">36403456</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Husain, J. M., Cromartie, D., Fitzelle-Jones, E., Brochier, A., Borba, C. P. C., &amp; Montalvo, C. (2023). A qualitative analysis of barriers to opioid agonist treatment for Racial/ethnic minoritized populations. <italic toggle="yes">Journal of Substance Abuse Treatment</italic>, <italic toggle="yes">144</italic>, 108918. 10.1016/j.jsat.2022.108918<pub-id pub-id-type="pmid">36403456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2022.108918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><mixed-citation publication-type="other">Jalal, H., Buchanich, J. M., Roberts, M. S., Balmert, L. C., Zhang, K., &amp; Burke, D. S. (2018). Changing dynamics of the drug overdose epidemic in the united States from 1979 through 2016. <italic toggle="yes">Science</italic>, <italic toggle="yes">361</italic>(6408). 10.1126/science.aau1184<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aau1184</pub-id><pub-id pub-id-type="pmcid">PMC8025225</pub-id><pub-id pub-id-type="pmid">30237320</pub-id></mixed-citation></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>K</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>A</given-names></name></person-group><article-title>The opioid crisis in black communities</article-title><source>Journal of Law Medicine &amp; Ethics</source><year>2018</year><volume>46</volume><issue>2</issue><fpage>404</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1177/1073110518782949</pub-id><pub-id pub-id-type="pmid">30146996</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">James, K., &amp; Jordan, A. (2018). The opioid crisis in black communities. <italic toggle="yes">Journal of Law Medicine &amp; Ethics</italic>, <italic toggle="yes">46</italic>(2), 404&#8211;421. 10.1177/1073110518782949<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1073110518782949</pub-id><pub-id pub-id-type="pmid">30146996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Redwood</surname><given-names>Y</given-names></name></person-group><article-title>The health care institution, population health and black lives</article-title><source>Journal of the National Medical Association</source><year>2016</year><volume>108</volume><issue>2</issue><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jnma.2016.04.002</pub-id><pub-id pub-id-type="pmid">27372475</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">King, C. J., &amp; Redwood, Y. (2016). The health care institution, population health and black lives. <italic toggle="yes">Journal of the National Medical Association</italic>, <italic toggle="yes">108</italic>(2), 131&#8211;136. 10.1016/j.jnma.2016.04.002<pub-id pub-id-type="pmid">27372475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jnma.2016.04.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>HK</given-names></name><name name-style="western"><surname>Roman</surname><given-names>PM</given-names></name></person-group><article-title>Racial and ethnic composition as a correlate of medication availability within addiction treatment organizations</article-title><source>Sociological Focus</source><year>2009</year><volume>42</volume><fpage>133</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1080/00380237.2009.10571347</pub-id><pub-id pub-id-type="pmid">20414366</pub-id><pub-id pub-id-type="pmcid">PMC2857917</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Knudsen, H. K., &amp; Roman, P. M. (2009). Racial and ethnic composition as a correlate of medication availability within addiction treatment organizations. <italic toggle="yes">Sociological Focus</italic>, <italic toggle="yes">42</italic>, 133&#8211;151.<pub-id pub-id-type="pmid">20414366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00380237.2009.10571347</pub-id><pub-id pub-id-type="pmcid">PMC2857917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagisetty</surname><given-names>PA</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A</given-names></name><name name-style="western"><surname>Clay</surname><given-names>M</given-names></name><name name-style="western"><surname>Maust</surname><given-names>DT</given-names></name></person-group><article-title>Buprenorphine treatment divide by race/ethnicity and payment</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><issue>9</issue><fpage>979</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.0876</pub-id><pub-id pub-id-type="pmid">31066881</pub-id><pub-id pub-id-type="pmcid">PMC6506898</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., &amp; Maust, D. T. (2019). Buprenorphine treatment divide by race/ethnicity and payment. <italic toggle="yes">JAMA Psychiatry</italic>, <italic toggle="yes">76</italic>(9), 979&#8211;981. 10.1001/jamapsychiatry.2019.0876<pub-id pub-id-type="pmid">31066881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2019.0876</pub-id><pub-id pub-id-type="pmcid">PMC6506898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>LA</given-names></name><name name-style="western"><surname>Peltzman</surname><given-names>T</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>JF</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>EM</given-names></name><name name-style="western"><surname>Trafton</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></name></person-group><article-title>Changing trends in opioid overdose deaths and prescription opioid receipt among veterans</article-title><source>American Journal of Preventive Medicine</source><year>2019</year><volume>57</volume><issue>1</issue><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2019.01.016</pub-id><pub-id pub-id-type="pmid">31128955</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lin, L. A., Peltzman, T., McCarthy, J. F., Oliva, E. M., Trafton, J. A., &amp; Bohnert, A. S. B. (2019). Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. <italic toggle="yes">American Journal of Preventive Medicine</italic>, <italic toggle="yes">57</italic>(1), 106&#8211;110. 10.1016/j.amepre.2019.01.016<pub-id pub-id-type="pmid">31128955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2019.01.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mark</surname><given-names>TL</given-names></name><name name-style="western"><surname>Goode</surname><given-names>LSA</given-names></name><name name-style="western"><surname>McMurtrie</surname><given-names>G</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>L</given-names></name><name name-style="western"><surname>Perry</surname><given-names>RJ</given-names></name></person-group><article-title>Improving research on Racial disparities in access to medications to treat opioid use disorders</article-title><source>Journal of Addiction Medicine</source><year>2023</year><volume>17</volume><issue>3</issue><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000001104</pub-id><pub-id pub-id-type="pmid">37267162</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mark, T. L., Goode, L. S. A., McMurtrie, G., Weinstein, L., &amp; Perry, R. J. (2023). Improving research on Racial disparities in access to medications to treat opioid use disorders. <italic toggle="yes">Journal of Addiction Medicine</italic>, <italic toggle="yes">17</italic>(3), 249&#8211;257. 10.1097/ADM.0000000000001104<pub-id pub-id-type="pmid">37267162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000001104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsden</surname><given-names>J</given-names></name><name name-style="western"><surname>Stillwell</surname><given-names>G</given-names></name><name name-style="western"><surname>Jones</surname><given-names>H</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>A</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>B</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>M</given-names></name><name name-style="western"><surname>Lowden</surname><given-names>T</given-names></name><name name-style="western"><surname>Maddalena</surname><given-names>N</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>C</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M</given-names></name></person-group><article-title>Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A National prospective observational study in England</article-title><source>Addiction</source><year>2017</year><volume>112</volume><issue>8</issue><fpage>1408</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1111/add.13779</pub-id><pub-id pub-id-type="pmid">28160345</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Marsden, J., Stillwell, G., Jones, H., Cooper, A., Eastwood, B., Farrell, M., Lowden, T., Maddalena, N., Metcalfe, C., Shaw, J., &amp; Hickman, M. (2017). Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A National prospective observational study in England. <italic toggle="yes">Addiction</italic>, <italic toggle="yes">112</italic>(8), 1408&#8211;1418. 10.1111/add.13779<pub-id pub-id-type="pmid">28160345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.13779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicosia</surname><given-names>N</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>JM</given-names></name><name name-style="western"><surname>Arkes</surname><given-names>J</given-names></name></person-group><article-title>Disparities in criminal court referrals to drug treatment and prison for minority men</article-title><source>American Journal of Public Health</source><year>2013</year><volume>103</volume><issue>6</issue><fpage>e77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2013.301222</pub-id><pub-id pub-id-type="pmid">23597342</pub-id><pub-id pub-id-type="pmcid">PMC3670657</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nicosia, N., Macdonald, J. M., &amp; Arkes, J. (2013). Disparities in criminal court referrals to drug treatment and prison for minority men. <italic toggle="yes">American Journal of Public Health</italic>, <italic toggle="yes">103</italic>(6), e77&#8211;84. 10.2105/AJPH.2013.301222<pub-id pub-id-type="pmid">23597342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2013.301222</pub-id><pub-id pub-id-type="pmcid">PMC3670657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettit</surname><given-names>B</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>C</given-names></name></person-group><article-title>Mass incarceration and Racial inequality</article-title><source>The American Journal of Economics and Sociology</source><year>2018</year><volume>77</volume><issue>3&#8211;4</issue><fpage>1153</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1111/ajes.12241</pub-id><pub-id pub-id-type="pmid">36213171</pub-id><pub-id pub-id-type="pmcid">PMC9540942</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Pettit, B., &amp; Gutierrez, C. (2018). Mass incarceration and Racial inequality. <italic toggle="yes">The American Journal of Economics and Sociology</italic>, <italic toggle="yes">77</italic>(3&#8211;4), 1153&#8211;1182. 10.1111/ajes.12241<pub-id pub-id-type="pmid">36213171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajes.12241</pub-id><pub-id pub-id-type="pmcid">PMC9540942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pro</surname><given-names>G</given-names></name><name name-style="western"><surname>Zaller</surname><given-names>N</given-names></name></person-group><article-title>Interaction effects in the association between methadone maintenance therapy and experiences of Racial discrimination in U.S. Healthcare settings</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>2</issue><fpage>e0228755</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0228755</pub-id><pub-id pub-id-type="pmid">32027723</pub-id><pub-id pub-id-type="pmcid">PMC7004348</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Pro, G., &amp; Zaller, N. (2020). Interaction effects in the association between methadone maintenance therapy and experiences of Racial discrimination in U.S. Healthcare settings. <italic toggle="yes">PLoS One</italic>, <italic toggle="yes">15</italic>(2), e0228755. 10.1371/journal.pone.0228755<pub-id pub-id-type="pmid">32027723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0228755</pub-id><pub-id pub-id-type="pmcid">PMC7004348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><mixed-citation publication-type="other">Ratcliffe, M., Burd, C., Holder, K., &amp; Fields, A. (2016). <italic toggle="yes">Defining rural at the U.S. Census Bureau</italic> (ACSGEO-1). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.census.gov/library/publications/2016/acs/acsgeo-1.html">https://www.census.gov/library/publications/2016/acs/acsgeo-1.html</ext-link></mixed-citation></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>RK</given-names></name><name name-style="western"><surname>Inose</surname><given-names>S</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>M</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></name><name name-style="western"><surname>Zalla</surname><given-names>LC</given-names></name><name name-style="western"><surname>Burlew</surname><given-names>AK</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>KE</given-names></name></person-group><article-title>Variation in opioid agonist dosing in clinical trials by race and ethnicity</article-title><source>JAMA Network Open</source><year>2024</year><volume>7</volume><issue>10</issue><fpage>e2436612</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.36612</pub-id><pub-id pub-id-type="pmid">39365581</pub-id><pub-id pub-id-type="pmcid">PMC11581645</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., &amp; Rudolph, K. E. (2024). Variation in opioid agonist dosing in clinical trials by race and ethnicity. <italic toggle="yes">JAMA Network Open</italic>, <italic toggle="yes">7</italic>(10), e2436612. 10.1001/jamanetworkopen.2024.36612<pub-id pub-id-type="pmid">39365581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.36612</pub-id><pub-id pub-id-type="pmcid">PMC11581645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M</given-names></name><name name-style="western"><surname>Toure</surname><given-names>J</given-names></name><name name-style="western"><surname>Tippens</surname><given-names>KM</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>C</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S</given-names></name></person-group><article-title>Racial and ethnic disparities in the VA health care system: A systematic review</article-title><source>Journal of General Internal Medicine</source><year>2008</year><volume>23</volume><issue>5</issue><fpage>654</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1007/s11606-008-0521-4</pub-id><pub-id pub-id-type="pmid">18301951</pub-id><pub-id pub-id-type="pmcid">PMC2324157</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Saha, S., Freeman, M., Toure, J., Tippens, K. M., Weeks, C., &amp; Ibrahim, S. (2008). Racial and ethnic disparities in the VA health care system: A systematic review. <italic toggle="yes">Journal of General Internal Medicine</italic>, <italic toggle="yes">23</italic>(5), 654&#8211;671. 10.1007/s11606-008-0521-4<pub-id pub-id-type="pmid">18301951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-008-0521-4</pub-id><pub-id pub-id-type="pmcid">PMC2324157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saloner</surname><given-names>B</given-names></name><name name-style="western"><surname>McGinty</surname><given-names>EE</given-names></name><name name-style="western"><surname>Beletsky</surname><given-names>L</given-names></name><name name-style="western"><surname>Bluthenthal</surname><given-names>R</given-names></name><name name-style="western"><surname>Beyrer</surname><given-names>C</given-names></name><name name-style="western"><surname>Botticelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>SG</given-names></name></person-group><article-title>A public health strategy for the opioid crisis</article-title><source>Public Health Reports</source><year>2018</year><volume>133</volume><issue>1_suppl</issue><fpage>24S</fpage><lpage>34S</lpage><pub-id pub-id-type="doi">10.1177/0033354918793627</pub-id><pub-id pub-id-type="pmid">30426871</pub-id><pub-id pub-id-type="pmcid">PMC6243441</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Saloner, B., McGinty, E. E., Beletsky, L., Bluthenthal, R., Beyrer, C., Botticelli, M., &amp; Sherman, S. G. (2018). A public health strategy for the opioid crisis. <italic toggle="yes">Public Health Reports</italic>, <italic toggle="yes">133</italic>(1_suppl), 24S&#8211;34S. 10.1177/0033354918793627<pub-id pub-id-type="pmid">30426871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0033354918793627</pub-id><pub-id pub-id-type="pmcid">PMC6243441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><mixed-citation publication-type="other">SAS Institute Inc. (2013). <italic toggle="yes">SAS/ACCESS</italic><sup><italic toggle="yes">&#174;</italic></sup><italic toggle="yes">9.4 Interface to ADABAS: Reference. [Computer software]</italic>. SAS Institute Inc.</mixed-citation></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>CK</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>ML</given-names></name><name name-style="western"><surname>Grella</surname><given-names>CE</given-names></name><name name-style="western"><surname>Mischel</surname><given-names>AF</given-names></name><name name-style="western"><surname>Carnevale</surname><given-names>J</given-names></name></person-group><article-title>The impact of the opioid crisis on U.S. State prison systems</article-title><source>Health Justice</source><year>2021</year><volume>9</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s40352-021-00143-9</pub-id><pub-id pub-id-type="pmid">34304335</pub-id><pub-id pub-id-type="pmcid">PMC8310396</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Scott, C. K., Dennis, M. L., Grella, C. E., Mischel, A. F., &amp; Carnevale, J. (2021). The impact of the opioid crisis on U.S. State prison systems. <italic toggle="yes">Health Justice</italic>, <italic toggle="yes">9</italic>(1), 17. 10.1186/s40352-021-00143-9<pub-id pub-id-type="pmid">34304335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40352-021-00143-9</pub-id><pub-id pub-id-type="pmcid">PMC8310396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sufrin</surname><given-names>C</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>C</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Fiscella</surname><given-names>K</given-names></name><name name-style="western"><surname>Olson</surname><given-names>S</given-names></name><name name-style="western"><surname>Voegtline</surname><given-names>K</given-names></name><name name-style="western"><surname>Latkin</surname><given-names>C</given-names></name></person-group><article-title>Availability of medications for opioid use disorder in U.S. Jails</article-title><source>Journal of General Internal Medicine</source><year>2023</year><volume>38</volume><issue>6</issue><fpage>1573</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1007/s11606-022-07812-x</pub-id><pub-id pub-id-type="pmid">36376631</pub-id><pub-id pub-id-type="pmcid">PMC10160287</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Sufrin, C., Kramer, C., Terplan, M., Fiscella, K., Olson, S., Voegtline, K., &amp; Latkin, C. (2023). Availability of medications for opioid use disorder in U.S. Jails. <italic toggle="yes">Journal of General Internal Medicine</italic>, <italic toggle="yes">38</italic>(6), 1573&#8211;1575. 10.1007/s11606-022-07812-x<pub-id pub-id-type="pmid">36376631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-022-07812-x</pub-id><pub-id pub-id-type="pmcid">PMC10160287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><mixed-citation publication-type="other">The Commonwealth of Massachusetts. (2024). <italic toggle="yes">Outcomes of the medications for opioid use disorder (MOUD) in correctional facilities pilot program</italic>. Department of Public Health, Executive Office of Health and Human Services. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mass.gov/doc/chapter-208-2024-legislative-report/download">https://www.mass.gov/doc/chapter-208-2024-legislative-report/download</ext-link> The Commonwealth of Massachusetts.</mixed-citation></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kasprow</surname><given-names>WJ</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>JF</given-names></name></person-group><article-title>Risk of incarceration and clinical characteristics of incarcerated veterans by race/ethnicity</article-title><source>Social Psychiatry and Psychiatric Epidemiology</source><year>2013</year><volume>48</volume><issue>11</issue><fpage>1777</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1007/s00127-013-0677-z</pub-id><pub-id pub-id-type="pmid">23508369</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Tsai, J., Rosenheck, R. A., Kasprow, W. J., &amp; McGuire, J. F. (2013). Risk of incarceration and clinical characteristics of incarcerated veterans by race/ethnicity. <italic toggle="yes">Social Psychiatry and Psychiatric Epidemiology</italic>, <italic toggle="yes">48</italic>(11), 1777&#8211;1786.<pub-id pub-id-type="pmid">23508369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00127-013-0677-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>Jones</surname><given-names>EB</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>EM</given-names></name></person-group><article-title>Prevention and treatment of opioid misuse and addiction: A review</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><issue>2</issue><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.3126</pub-id><pub-id pub-id-type="pmid">30516809</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Volkow, N. D., Jones, E. B., Einstein, E. B., &amp; Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction: A review. <italic toggle="yes">JAMA Psychiatry</italic>, <italic toggle="yes">76</italic>(2), 208&#8211;216. 10.1001/jamapsychiatry.2018.3126<pub-id pub-id-type="pmid">30516809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2018.3126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkelman</surname><given-names>TN</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>EC</given-names></name><name name-style="western"><surname>Goold</surname><given-names>SD</given-names></name><name name-style="western"><surname>Morenoff</surname><given-names>JD</given-names></name><name name-style="western"><surname>Cross</surname><given-names>K</given-names></name><name name-style="western"><surname>Ayanian</surname><given-names>JZ</given-names></name></person-group><article-title>Health insurance trends and access to behavioral healthcare among justice-involved individuals-United States, 2008&#8211;2014</article-title><source>Journal of General Internal Medicine</source><year>2016</year><pub-id pub-id-type="doi">10.1007/s11606-016-3845-5</pub-id><pub-id pub-id-type="pmcid">PMC5130958</pub-id><pub-id pub-id-type="pmid">27638837</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Winkelman, T. N., Kieffer, E. C., Goold, S. D., Morenoff, J. D., Cross, K., &amp; Ayanian, J. Z. (2016). Health insurance trends and access to behavioral healthcare among justice-involved individuals-United States, 2008&#8211;2014. <italic toggle="yes">Journal of General Internal Medicine</italic>. 10.1007/s11606-016-3845-5<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11606-016-3845-5</pub-id><pub-id pub-id-type="pmcid">PMC5130958</pub-id><pub-id pub-id-type="pmid">27638837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyse</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dobscha</surname><given-names>SK</given-names></name><name name-style="western"><surname>Morasco</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Tiffany</surname><given-names>E</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>K</given-names></name><name name-style="western"><surname>Sandbrink</surname><given-names>F</given-names></name><name name-style="western"><surname>Lovejoy</surname><given-names>TI</given-names></name></person-group><article-title>Medications for opioid use disorder in the department of veterans affairs (VA) health care system: Historical perspective, lessons learned, and next steps</article-title><source>Substance Abuse</source><year>2018</year><volume>39</volume><issue>2</issue><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1080/08897077.2018.1452327</pub-id><pub-id pub-id-type="pmid">29595375</pub-id><pub-id pub-id-type="pmcid">PMC8054831</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Wyse, J. J., Gordon, A. J., Dobscha, S. K., Morasco, B. J., Tiffany, E., Drexler, K., Sandbrink, F., &amp; Lovejoy, T. I. (2018). Medications for opioid use disorder in the department of veterans affairs (VA) health care system: Historical perspective, lessons learned, and next steps. <italic toggle="yes">Substance Abuse</italic>, <italic toggle="yes">39</italic>(2), 139&#8211;144. 10.1080/08897077.2018.1452327<pub-id pub-id-type="pmid">29595375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2018.1452327</pub-id><pub-id pub-id-type="pmcid">PMC8054831</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>